ArticleBMJ open respiratory research2025
Increased risk of acute exacerbation in obstructive airway disease: the impact of metabolic dysfunction-associated steatotic liver disease and small airway dysfunction.
Article in BMJ open respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Metabolic Dysfunction-Associated Steatotic Liver Disease and Respiratory Disorders: A Systematic Review of Clinical and Pathophysiological Associations.Current obesity reports · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND STUDY
aimMetabolic dysfunction-associated steatotic liver disease (MASLD) is a common metabolic and liver condition that leads to systemic inflammation. Obstructive airway diseases (OADs) are characterised by chronic airway inflammation, with small airway dysfunction (SAD) regarded as an early indicator. However, it is unknown whether MASLD contributes to SAD or the risk of acute exacerbation (AE) in OAD.
methodsIn this retrospective cohort study, 2572 patients who underwent spirometry, impulse oscillometry (IOS) and abdominal CT scans were enrolled. Patients were divided according to MASLD status to compare their pulmonary function and clinical outcomes, including OAD AE over a follow-up period of up to 6 years.
results349 patients exhibited MASLD (13.6%). The peripheral airway resistance measured by IOS is significantly higher in MASLD patients (X5 values: -0.14 vs -0.16 kPa/(L/s), p=0.002; AX: 0.76 vs 0.89, p=0.044). After 6 years of follow-up, patients with both MASLD and SAD exhibited the highest rate of OAD AE (34.8%, p=0.016) of all groups, and the coexistence of MASLD and SAD remained an independent predictor of exacerbations after adjustment by logistic regression. Hepatic steatosis was also identified as a potential contributing factor of OAD AE.
conclusionMASLD is associated with a higher risk of SAD, and together they markedly increase OAD AE risk. Hepatic steatosis appears to be a major driver of this risk. These findings highlight the need for integrated management of patients with MASLD, addressing both liver and respiratory health to improve outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.